Research ArticleArticle
Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
Gregory McDermott, Ritu Gill, Staci Gagne, Suzanne Byrne, Weixing Huang, Xiaosong Wang, Lauren C. Prisco, Alessandra Zaccardelli, Lily W. Martin, Lucy Masto, Vanessa L. Kronzer, Nancy Shadick, Paul F. Dellaripa, Tracy J. Doyle and Jeffrey A. Sparks
The Journal of Rheumatology March 2022, jrheum.211242; DOI: https://doi.org/10.3899/jrheum.211242
Gregory McDermott
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Ritu Gill
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Staci Gagne
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Suzanne Byrne
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Weixing Huang
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Xiaosong Wang
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Lauren C. Prisco
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Alessandra Zaccardelli
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Lily W. Martin
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Lucy Masto
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Vanessa L. Kronzer
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Nancy Shadick
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Paul F. Dellaripa
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Tracy J. Doyle
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Jeffrey A. Sparks
GM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR055855). JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577) and the R. Bruce and Joan M. Mickey Research Scholar Fund. TJD is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH; grant nos. K23 HL119558 and R03 HL148484). The funders had no role in the decision to publish or in the preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centers, or the NIH. G. McDermott, MD, N. Shadick, MD, MPH, P.F. Dellaripa, MD, J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; R. Gill, MD, Department of Radiology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts; S. Gagne, MD, S. Byrne, MD, Department of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts; W. Huang, MSPH, X. Wang, MS, L.C. Prisco, BA, A. Zaccardelli, MS, L.W. Martin, BS, L. Masto, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts; V.L. Kronzer, MD, MSCI, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota; T.J. Doyle, MD, MPH, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. JAS has received research support from BMS and has performed consultancy for AbbVie, Boehringer Ingelheim, BMS, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. NS reports research support from Mallinckrodt, BMS, Amgen, and Lilly, and has performed consultancy for BMS unrelated to this work. TJD reports grant funding and other support from MBS and Genentech, and personal fees from Boehringer Ingelheim and L.E.K. Consulting unrelated to this study. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. J.A. Sparks, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA. Email: jsparks@bwh.harvard.edu. Accepted for publication March 8, 2022.
Abstract
Objective To investigate demographic, lifestyle, and serologic risk factors for isolated rheumatoid arthritis (RA)–associated bronchiectasis (RA-BR) that is not a result of interstitial lung disease (ILD).
Methods We performed a case-control study using patients with RA from the Mass General Brigham Biobank. We reviewed the records of all patients with RA meeting the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria with computed tomography (CT) chest imaging to identify RA-BR cases and controls with RA and RA-related lung disease. For each patient, the CT chest imaging that was performed closest to enrollment was independently reviewed by 2 radiologists for the presence of RA-related lung diseases. Cases had clinical and radiologic evidence of RA-BR without interstitial lung abnormalities on imaging. Controls had RA and no evidence of bronchiectasis or ILD. We examined the associations between demographic, lifestyle, and serologic factors with RA-BR using multivariable logistic regression.
Results We identified 57 cases of isolated RA-BR and 360 RA controls without RA-related lung disease. In multivariable models, RA-BR was associated with older age at RA onset (OR 1.37 per 10 years, 95% CI 1.02–1.82), lower BMI at RA diagnosis (OR 0.94 per kg/m2, 95% CI 0.89–0.99), seropositive RA (OR 3.96, 95% CI 1.84–8.53), positive rheumatoid factor (OR 4.40, 95% CI 2.14–9.07), and positive anticyclic citrullinated peptide (OR 3.47, 95% CI 1.65–7.31). Higher titers of RA-related autoantibodies were associated with higher odds of RA-BR.
Conclusion Seropositivity, older age at RA diagnosis, and lower BMI at RA onset were associated with isolated bronchiectasis in RA that was not a result of ILD. These findings expand the list of potential risk factors for RA-BR and suggest a pathogenic link between airway inflammation and RA-related autoantibodies.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
The Journal of Rheumatology
Vol. 49, Issue 8
1 Aug 2022
Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
Gregory McDermott, Ritu Gill, Staci Gagne, Suzanne Byrne, Weixing Huang, Xiaosong Wang, Lauren C. Prisco, Alessandra Zaccardelli, Lily W. Martin, Lucy Masto, Vanessa L. Kronzer, Nancy Shadick, Paul F. Dellaripa, Tracy J. Doyle, Jeffrey A. Sparks
The Journal of Rheumatology Mar 2022, jrheum.211242; DOI: 10.3899/jrheum.211242
Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
Gregory McDermott, Ritu Gill, Staci Gagne, Suzanne Byrne, Weixing Huang, Xiaosong Wang, Lauren C. Prisco, Alessandra Zaccardelli, Lily W. Martin, Lucy Masto, Vanessa L. Kronzer, Nancy Shadick, Paul F. Dellaripa, Tracy J. Doyle, Jeffrey A. Sparks
The Journal of Rheumatology Mar 2022, jrheum.211242; DOI: 10.3899/jrheum.211242
